Vaxart will release Phase I trial data for its norovirus vaccine on June 11, 2025, followed by a management conference call.
Quiver AI Summary
Vaxart, Inc., a biotechnology company focused on oral recombinant pill vaccines, announced it will release topline data from its Phase I trial on norovirus before the market opens on June 11, 2025. A conference call hosted by the senior management team will take place the same day at 8:30 a.m. Eastern Time to discuss the data and provide trial updates. Investors can access the call via a provided webcast or by phone, and are encouraged to submit questions in advance. Vaxart's innovative oral vaccine platform aims to provide non-refrigerated vaccine options, and the company's development programs include vaccines for norovirus, coronavirus, influenza, and HPV.
Potential Positives
- Announcement of topline data release from the norovirus Phase I trial indicates progress in clinical development, which is significant for the company’s credibility and future funding opportunities.
- The live conference call to discuss the data reflects transparency and investor engagement, potentially boosting investor confidence.
- The focus on developing oral vaccines positions Vaxart as a pioneer in the market, highlighting the innovative nature of their proprietary delivery platform.
- Broad domestic and international patent applications protect Vaxart’s technology, which may enhance its competitive advantage and foster future partnerships.
Potential Negatives
- Although Vaxart is announcing topline data from a Phase I trial, there is no indication of the trial's success or specifics about results, which may raise concerns about the company's progress and efficacy of its vaccine candidates.
- The release provides minimal detail regarding the actual findings of the trial, potentially leading to uncertainty among investors and stakeholders about the company's future direction and viability.
- Being a clinical-stage company, any negative outcomes from the forthcoming data could significantly impact investor confidence and stock performance.
FAQ
When will Vaxart announce the Phase I trial data?
Vaxart will release the topline data from the norovirus Phase I trial on June 11, 2025, before the market opens.
How can I join the Vaxart conference call?
The conference call can be accessed on June 11, 2025, at 8:30 a.m. ET via domestic phone at (877) 407-0832 or international at (201) 689-8433.
Where can I find the webcast replay?
A replay of the webcast will be available on Vaxart’s website after the conclusion of the event.
What types of vaccines is Vaxart developing?
Vaxart is developing oral recombinant vaccines targeting norovirus, coronavirus, influenza, and a therapeutic vaccine for HPV.
How are Vaxart's vaccines stored and administered?
The vaccines are in pill form, can be stored without refrigeration, and eliminate the risk of needle-stick injury.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$VXRT Insider Trading Activity
$VXRT insiders have traded $VXRT stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $VXRT stock by insiders over the last 6 months:
- STEVEN LO (President, Chief Exec Officer) purchased 100,000 shares for an estimated $49,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$VXRT Hedge Fund Activity
We have seen 26 institutional investors add shares of $VXRT stock to their portfolio, and 54 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIO CAPITAL MANAGEMENT, LLC removed 5,931,867 shares (-51.5%) from their portfolio in Q1 2025, for an estimated $2,414,269
- MILLENNIUM MANAGEMENT LLC removed 2,034,776 shares (-68.0%) from their portfolio in Q1 2025, for an estimated $828,153
- CITADEL ADVISORS LLC removed 501,623 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $204,160
- JONES FINANCIAL COMPANIES LLLP added 478,111 shares (+276364.7%) to their portfolio in Q1 2025, for an estimated $194,591
- SILVERARC CAPITAL MANAGEMENT, LLC removed 393,957 shares (-36.6%) from their portfolio in Q1 2025, for an estimated $160,340
- VANGUARD GROUP INC added 291,506 shares (+2.9%) to their portfolio in Q1 2025, for an estimated $118,642
- SQUAREPOINT OPS LLC added 287,677 shares (+55.7%) to their portfolio in Q1 2025, for an estimated $117,084
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update.
The conference call can be accessed using the following information:
Webcast:
Click here
Date: Wednesday, June 11, 2025 – 8:30 a.m. ET
Domestic: (877) 407-0832
International: (201) 689-8433
Conference ID: 13754315
Investors may submit written questions in advance of the conference call to [email protected] .
A replay of the webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
| Vaxart Media and Investor Relations: |
| Matt Steinberg |
| FINN Partners |
| [email protected] |
| (646) 871-8481 |
This press release was published by a CLEAR® Verified individual.
